LLY

765.17

-2.47%↓

JNJ

149.65

-0.8%↓

NVO

73.86

-0.31%↓

ABBV

185.03

-0.19%↓

UNH

301.85

-1.71%↓

LLY

765.17

-2.47%↓

JNJ

149.65

-0.8%↓

NVO

73.86

-0.31%↓

ABBV

185.03

-0.19%↓

UNH

301.85

-1.71%↓

LLY

765.17

-2.47%↓

JNJ

149.65

-0.8%↓

NVO

73.86

-0.31%↓

ABBV

185.03

-0.19%↓

UNH

301.85

-1.71%↓

LLY

765.17

-2.47%↓

JNJ

149.65

-0.8%↓

NVO

73.86

-0.31%↓

ABBV

185.03

-0.19%↓

UNH

301.85

-1.71%↓

LLY

765.17

-2.47%↓

JNJ

149.65

-0.8%↓

NVO

73.86

-0.31%↓

ABBV

185.03

-0.19%↓

UNH

301.85

-1.71%↓

Search

Atossa Genetics Inc

Geschlossen

0.78 -2.5

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

0.78

Max

0.79

Schlüsselkennzahlen

By Trading Economics

Einkommen

-371K

-6.7M

EPS

-0.05

Angestellte

15

EBITDA

-766K

-7.1M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+612.66% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

11. Aug. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

1.8M

110M

Vorheriger Eröffnungskurs

3.28

Vorheriger Schlusskurs

0.78

Technischer Score

By Trading Central

Vertrauen

Bullish Evidence

Atossa Genetics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

20. Juni 2025, 18:52 UTC

Ergebnisse

Accenture Shares Fall on Bookings Decline, Concerns over Federal Government Contract -- 3rd Update

20. Juni 2025, 16:15 UTC

Akquisitionen, Fusionen, Übernahmen

Canadian Natural Selling Control of Gas Plant to Secure Approval for Schlumberger Deal

20. Juni 2025, 20:50 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Financial Services Roundup: Market Talk

20. Juni 2025, 20:50 UTC

Market Talk
Ergebnisse

Tech, Media & Telecom Roundup: Market Talk

20. Juni 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

20. Juni 2025, 20:13 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

These Stocks Moved the Most Today: Tesla, Accenture, GMS, CarMax, Circle Internet, Smith & Wesson, Kroger, and More -- Barrons.com

20. Juni 2025, 20:11 UTC

Market Talk

Natural Gas Slides in Late-Week Profit Taking -- Market Talk

20. Juni 2025, 19:56 UTC

Market Talk

Crude Oil Slips to End Week -- Market Talk

20. Juni 2025, 18:35 UTC

Market Talk

Warehouse Clubs Seen Growing Market Share -- Market Talk

20. Juni 2025, 18:12 UTC

Market Talk

Gold Slides to Close Shortened Week -- Market Talk

20. Juni 2025, 17:56 UTC

Market Talk

Baker Hughes Reports Slight Decrease in U.S. Rig Count -- Market Talk

20. Juni 2025, 17:50 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

These Stocks Are Moving the Most Today: Tesla, Accenture, GMS, CarMax, Circle Internet, Smith & Wesson, Kroger, and More -- Barrons.com

20. Juni 2025, 17:35 UTC

Akquisitionen, Fusionen, Übernahmen

Cisco Was the Dot-Com Bust's Biggest Loser. Now It's at a 25-Year High. -- Barrons.com

20. Juni 2025, 17:30 UTC

Market Talk
Ergebnisse

Adobe's AI Headwinds Seen Fading -- Market Talk

20. Juni 2025, 17:03 UTC

Ergebnisse

Accenture Earnings Beat Expectations. Why the Stock Is Falling Anyway. -- Barrons.com

20. Juni 2025, 16:50 UTC

Market Talk
Ergebnisse

Global Equities Roundup: Market Talk

20. Juni 2025, 16:50 UTC

Market Talk
Ergebnisse

Accenture Seeing Companies Shift to Leapfrog Mentality -- Market Talk

20. Juni 2025, 16:44 UTC

Akquisitionen, Fusionen, Übernahmen

Meet QXO, the Upstart Building Materials Stock That May Battle Home Depot for GMS -- Barrons.com

20. Juni 2025, 16:40 UTC

Market Talk
Ergebnisse

Accenture Can't Yet Estimate Longer Term Impact from Federal Cuts -- Market Talk

20. Juni 2025, 16:20 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Financial Services Roundup: Market Talk

20. Juni 2025, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

20. Juni 2025, 16:17 UTC

Akquisitionen, Fusionen, Übernahmen

UniCredit: ULI and UVA Are Expected to Merge in 2026

20. Juni 2025, 16:17 UTC

Akquisitionen, Fusionen, Übernahmen

UniCredit: Alessandro Santoliquido has been appointed CEO of both companies alongside his role as Head of Group Insurance

20. Juni 2025, 16:05 UTC

Market Talk

Gold Futures on Track to End Week Lower Despite Haven Demand -- Market Talk

20. Juni 2025, 15:56 UTC

Market Talk
Ergebnisse

Accenture Says Federal Business Had Immaterial Impact to Growth -- Market Talk

20. Juni 2025, 15:26 UTC

Market Talk

Natural Gas Slips After Streak of Higher Closes -- Market Talk

20. Juni 2025, 15:25 UTC

Akquisitionen, Fusionen, Übernahmen

Regulator Says Satisfied Sale Would Preserve Competition in Area Around Seiu Processing Plant

20. Juni 2025, 15:25 UTC

Akquisitionen, Fusionen, Übernahmen

Competition Bureau Says Canadian Natural to Sell 75% Stake in Seiu Lake Natural Gas Plant to North 40 Resources

20. Juni 2025, 15:25 UTC

Akquisitionen, Fusionen, Übernahmen

Canada Antitrust Regulation Reaches Agreement With Canadian Natural Resources Over Proposed Buy of Schlumberger JV Interest

20. Juni 2025, 15:09 UTC

Market Talk

Canadian Retail Sales Show Reversal of Tariff Front-Running -- Market Talk

Peer-Vergleich

Kursveränderung

Atossa Genetics Inc Prognose

Kursziel

By TipRanks

612.66% Vorteil

12-Monats-Prognose

Durchschnitt 5.63 USD  612.66%

Hoch 7.5 USD

Tief 4 USD

Basierend auf 4 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Atossa Genetics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

4 ratings

4

Buy

0

Halten

0

Sell

Technischer Score

By Trading Central

0.7955 / 0.898Unterstützung & Widerstand

Kurzfristig

Bullish Evidence

Mittelfristig

Strong Bullish Evidence

Langfristig

Weak Bearish Evidence

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Atossa Genetics Inc

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.